GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » PB Ratio

Axsome Therapeutics (Axsome Therapeutics) PB Ratio : 17.75 (As of Apr. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Axsome Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), Axsome Therapeutics's share price is $71.585. Axsome Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $4.03. Hence, Axsome Therapeutics's PB Ratio of today is 17.75.

The historical rank and industry rank for Axsome Therapeutics's PB Ratio or its related term are showing as below:

AXSM' s PB Ratio Range Over the Past 10 Years
Min: 10.08   Med: 20.55   Max: 176.19
Current: 17.76

During the past 11 years, Axsome Therapeutics's highest PB Ratio was 176.19. The lowest was 10.08. And the median was 20.55.

AXSM's PB Ratio is ranked worse than
95.11% of 1310 companies
in the Biotechnology industry
Industry Median: 2.385 vs AXSM: 17.76

During the past 12 months, Axsome Therapeutics's average Book Value Per Share Growth Rate was 60.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 9.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 79.00% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Axsome Therapeutics was 137.10% per year. The lowest was -76.60% per year. And the median was 36.20% per year.

Back to Basics: PB Ratio


Axsome Therapeutics PB Ratio Historical Data

The historical data trend for Axsome Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics PB Ratio Chart

Axsome Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.36 26.76 91.48 30.62 19.73

Axsome Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.62 24.02 12.00 12.27 19.73

Competitive Comparison of Axsome Therapeutics's PB Ratio

For the Biotechnology subindustry, Axsome Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's PB Ratio falls into.



Axsome Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Axsome Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=71.585/4.033
=17.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Axsome Therapeutics  (NAS:AXSM) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Axsome Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Axsome Therapeutics (Axsome Therapeutics) Business Description

Traded in Other Exchanges
Address
22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.
Executives
Susan Mahony director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Mark Coleman director 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Hunter R. Murdock officer: General Counsel 22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007
Roger Jeffs director
Nick Pizzie officer: Chief Financial Officer 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Mark E Saad director C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Herriot Tabuteau director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER
Mark L. Jacobson officer: Chief Operating Officer 200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038
David C Marek officer: Chief Commercial Officer C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
John Golubieski officer: Chief Financial Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Randall Kaye officer: Chief Medical Officer 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Ames Constance officer: Vice President, Finance 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Antecip Capital Llc 10 percent owner 630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111

Axsome Therapeutics (Axsome Therapeutics) Headlines